Eldin Carole, Grossi Paolo Antonio, Manda Victoria, Kamar Nassim, Lortholary Olivier, Hirsch Hans H, Zahar Jean-Ralph, Borderie Vincent Michel, Parquin François, Epailly Eric, Ader Florence, Morelon Emmanuel, Forcade Edouard, Lebeaux David, Dumortier Jérôme, Conti Filomena, Lefort Agnes, Scemla Anne, Kaminski Hannah
Maladies infectieuses et Tropicales - CHU Nord, Unité des Virus Emergents (UVE), (Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), Marseille, France.
Infectious and tropical Diseases Unit, Department of Medicine and Surgery- ASST-Sette Laghi, University of Insubria, Varese, Italy.
Transpl Int. 2025 Aug 13;38:14237. doi: 10.3389/ti.2025.14237. eCollection 2025.
The annual meeting of the French GTI (Transplantation and Infection Group) focused on donor-derived infections (DDIs) in solid organ transplant (SOT) recipients. Given the ongoing organ shortage, rigorous donor screening is essential to detect potential infectious risks. Donor evaluation should include medical history, travel, vaccination status, serologies, and exposures. Various pathogens are of concern, including viruses (HIV, hepatitis, BK polyomavirus), multidrug-resistant bacteria, fungi, and emerging arboviruses like West Nile virus and dengue. HIV-positive donor to HIV-positive recipient (D+/R+) transplantations are increasingly accepted, with promising outcomes. Hepatitis E (HEV) is now the most common viral hepatitis and may lead to chronic infection in SOT recipients, requiring ribavirin treatment. Non-Candida fungal infections, though rare, are associated with high mortality and demand early recognition. Climate change and globalization are expanding the range of vector-borne infections, necessitating seasonal and regional screening. BK polyomavirus remains a major complication in kidney transplant recipients, and monitoring viral load is critical. Bacterial infections from donors are uncommon but should be evaluated based on site, organism, resistance profile, and treatment history. Overall, maintaining safety in transplantation requires constant vigilance, updated knowledge, and personalized risk-benefit analysis to adapt to emerging infectious threats-especially amid ongoing organ scarcity.
法国移植与感染小组(GTI)的年会聚焦于实体器官移植(SOT)受者的供体源性感染(DDIs)。鉴于器官持续短缺,严格的供体筛查对于检测潜在感染风险至关重要。供体评估应包括病史、旅行史、疫苗接种状况、血清学检查和接触史。多种病原体都值得关注,包括病毒(艾滋病毒、肝炎病毒、BK多瘤病毒)、多重耐药细菌、真菌以及西尼罗河病毒和登革热等新出现的虫媒病毒。艾滋病毒阳性供体到艾滋病毒阳性受者(D+/R+)的移植越来越被接受,且结果令人鼓舞。戊型肝炎(HEV)现在是最常见的病毒性肝炎,可能导致SOT受者慢性感染,需要使用利巴韦林治疗。非念珠菌真菌感染虽然罕见,但与高死亡率相关,需要早期识别。气候变化和全球化正在扩大虫媒传播感染的范围,因此需要进行季节性和区域性筛查。BK多瘤病毒仍然是肾移植受者的主要并发症,监测病毒载量至关重要。供体引起的细菌感染并不常见,但应根据感染部位、病原体、耐药情况和治疗史进行评估。总体而言,在移植过程中保持安全需要持续警惕、更新知识以及进行个性化的风险效益分析,以适应新出现的感染威胁——尤其是在器官持续短缺的情况下。